# Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma

> **NCT03616860** · NA · COMPLETED · sponsor: **InSightec** · enrollment: 14 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DEVICE:** Focused Ultrasound (FUS) BBB Disruption

## Key facts

- **NCT ID:** NCT03616860
- **Lead sponsor:** InSightec
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-16
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616860, "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03616860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*